Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Por:
Abraldes, MJ, Calvo, P, Lechuga, MG, Merino, M, Lorenzo, TM, Maravilla-Herrera, P, Jiménez, BG, Ruiz-Moreno, JM
Publicada:
1 jul 2024
Ahead of Print:
1 may 2024
Resumen:
Introduction Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients' and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain.Methods The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021.Results The mean annual cost of nAMD was estimated at 17,265, 15,403, and 14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of 744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients' LPL was minimal.Conclusion This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.
Filiaciones:
Abraldes, MJ:
Complexo Hosp Univ Santiago, Med Retina & Ocular Diabet Unit, Santiago De Compostela, Spain
Calvo, P:
Hosp Univ Miguel Servet, Med Retina Unit, Zaragoza, Spain
Lechuga, MG:
Hosp Santa Creu & Sant Pau, Pharm Dept, Barcelona, Spain
Merino, M:
Weber, Hlth Outcomes Res Dept, C Moreto 17,5 Dcha, Madrid 28014, Spain
Lorenzo, TM:
Weber, Hlth Outcomes Res Dept, C Moreto 17,5 Dcha, Madrid 28014, Spain
Maravilla-Herrera, P:
Weber, Hlth Outcomes Res Dept, C Moreto 17,5 Dcha, Madrid 28014, Spain
Jiménez, BG:
Roche Farma, Pricing Dept, Madrid, Spain
Ruiz-Moreno, JM:
Hosp Univ Puerta Hierro, Ophtalmol Dept, Majadahonda, Spain
gold
|